Results 161 to 170 of about 519,059 (309)

A sustainable business ecosystem: a case study demonstrating biochar's potential

open access: yesBiofuels, Bioproducts and Biorefining, EarlyView.
Abstract The need for renewable, climate‐friendly resources has become urgent as legislators worldwide have sought to find ways to cut emissions while ensuring resource security for consumers. The use of biochar could help to achieve these goals. This study examines the current state of commercial biochar production and the maturity of the related ...
Kivijakola Juuso   +4 more
wiley   +1 more source

Stability of Monetary Unions: Lessons from the Break-up of Czechoslovakia [PDF]

open access: yes
In 1993, Czechoslovakia experienced a two-fold break-up: On January 1, the country disintegrated as a political union, while preserving an economic and monetary union. Then, the Czech-Slovak monetary union collapsed on February 8. We analyze the economic
Fidrmuc, Jan   +2 more
core  

Simulating competition in the US bioeconomy to produce hard‐to‐electrify transportation fuels using limited biomass resources

open access: yesBiofuels, Bioproducts and Biorefining, EarlyView.
Abstract This study presents a novel bioeconomy optimization framework, BiOpt, designed to address critical questions regarding the strategic use of limited US biomass resources for biofuel production. By integrating detailed techno‐economic analyses, life cycle assessments, and resource assessment data, BiOpt optimizes resource distributions across ...
Nicholas A. Carlson   +3 more
wiley   +1 more source

Determinants of the Public's Preference for a Referendum on Monetary Union [PDF]

open access: yes
Public support is crucial for the success of a monetary union. An aspect of the monetary unification process that could influence public support is how the decision to participate is made. This article analyzes the determinants of the public's preference
Steven Buigut
core  

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló   +5 more
wiley   +1 more source

Switzerland and Euroland: European Monetary Union, Monetary Stability and Financial Stability [PDF]

open access: yes
This contribution to the Festschrift for the Centenary of the Swiss National Bank discusses the prospects for monetary stability and financial stability after the creation of the European Monetary Union.
Martin Hellwig
core  

Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley   +1 more source

The monetary policy consequences of enlargement [PDF]

open access: yes
Europäische Wirtschafts- und Währungsunion, EU-Erweiterung, Geldpolitik, European Economic and Monetary Union, EU enlargement, Monetary ...
Carsten Hefeker
core  

The euro and the European Central Bank [PDF]

open access: yes
The formation of a monetary union by 11 European countries has received a lot of notice from the press since January 1, 1999, when the union's common currency, the euro, was officially introduced.
Jeffrey M. Wrase
core  

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Home - About - Disclaimer - Privacy